IDENTIFICATION OF A MULTI-ANALYTE PROFILE FOR PRIMARY HYPEROXALURIA AND COMPARISON WITH HEALTHY SIBLINGS AND IDIOPATHIC HYPERCALCIURIA

Primary Hyperoxaluria Type 1 Clinical Trial

— PH1  

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02830009
• Other study ID #: 2010-604
• Status: Completed
• Phase: N/A
• First received: July 8, 2016
• Last updated: July 12, 2016
• Start date: May 2013
• Est. completion date: December 2015

Study information

• Verified date: July 2016
• Source: Hospices Civils de Lyon
• Contact: n/a
• Is FDA regulated: No
• Health authority: France: Agence Nationale de Sécurité du Médicament et des produits de santé
• Study type: Interventional

Clinical Trial Summary

The aim of this study is to know the difference between protein profiles (multi-analyte profile) of PH1 patients, idiopathic hypercalciuria (IH) patients and PH1 patients 'siblings. Idiopathic hypercalciuria is a less severe kidney disease that PH1, which also leads to the formation of kidney stones.

The aim is to identify patterns of discriminating markers associated with primary hyperoxaluria type 1 (PH1) that will significantly improve clinical diagnosis and prognosis.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 5
• Est. completion date: December 2015
• Est. primary completion date: July 2013
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Diagnosed with primary hyperoxaluria, type 1 (PH1-Cohort A); OR

• Confirmed with AGXT mutation analysis (PH1-Cohort A)

• Diagnosed with idiopathic hypercalciuria (IHC- Cohort B);

• Potential subject diagnosed with PH1 or IH and has both data entered into the registry and has matched, archived random and 24-hour urine specimens obtained prior to any treatment intervention OR is consented and enrolled into the registry or this specific study during the program;

• Healthy siblings of PH1 patients known not to have PH or any another stone disease or chronic disease will be consented and enrolled into this study through the local sites where their sibling is being treated for PH1 (this study meets the criteria for expedited review through local or central IRBs);

• Healthy non-sibling controls known not to have PH or any another stone disease or chronic disease (Healthy Control-Cohort C);

• There is no upper or lower limit to the pediatric age range of enrolling infant, children and adolescent subjects, although it is understood that accurate and complete 24-hour urine collection in very young children and infants will be problematic and will be seriously considered in advance of individual patient or healthy controls enrollment;

• eGFR (Glomerular Filtration Rate) > 60 mL/min x 1.73 m2 with PH1 and IH patient cohorts matched by mean eGFR from their initial study (or registry) enrollment/ data collection.

Exclusion Criteria:

• Unwilling to provide written parent consent or adolescent assent to enroll into the International Registry or this study;

• Potential PH1, hypercalciuria, or siblings of PH1 patients with other chronic or acute illness or disease that could potentially confound proteomic results;

• Healthy intra-familial siblings unwilling to provide a blood sample for serum creatinine;

• Unwilling to provide urine specimens or permit data abstraction for the registry or this study.

• Not covered by, or having the right to, Social Security

Study Design

Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science

Related Conditions & MeSH terms

• Hypercalciuria
• Hyperoxaluria, Primary
• Idiopathic Hypercalciuria
• Primary Hyperoxaluria Type 1

Intervention

Other:
• Urines samples
24-hour urines will be collected
• Blood sample

Locations

Country	Name	City	State
France	Hospices Civils de Lyon	Lyon/bron

Sponsors (1)

Lead Sponsor	Collaborator
Hospices Civils de Lyon

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	presence of protein markers in urine		24 hours	No
Secondary	Presence of discriminative and robust protein markers in urine		24 hours	No